Metabolic platform

Metabolic Technology platform for preclinical contract research is under continuous development:

Metabolic (diabetes, hyperlipidemia, hypercholesterolemia, atherosclerosis, obesity, non-alcoholic fatty liver disease,
non-alcoholic steatohepatitis, and uremia) disease models:

  • acute diabetes models (toxin-induced, diet-induced)
  • chronic diabetes models (toxin-induced, neonatal STZ, Goto-Kakizaki, db/db mice)
  • metabolic disease models (diet and genetic models, e.g. Zucker Fatty rats, Zucker Diabetic Fatty rats, db/db mice)
  • hyperlipidemia models (hyperlipidemia and hypercholesterolemia induced by different types of high cholesterol and high fat diet, as well as genetic models)
  • atherosclerosis models
  • Several diet-induced (e.g. high fat diet, Methionine-Choline deficient diet, Choline Deficient L-Amino Acid defined (CDAA) diet, Western diet, etc.) small and large animal models of human non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH) with or without relevant co-morbidities such as obesity, insulin resistance and dyslipidemia, etc. with clinically relevant end-points e.g. histological and biochemical readouts.
  • obesity models (diet-induced and genetic models)
  • uremia models induced by partial nephrectomy

All models include metabolic biomarker assays, such as glucose, glucose-clamp, on-line OGT-test, insulin-tolerance test, insulin and related hormone assays, pancreatic insulin, serum and tissue lipid analysis, atherosclerotic plaque analysis, inflammatory biomarker and risk factor assays, as well as basic  metabolic parameters measured in metabolic cages.